Accelerating VHH-enabled Antibody-Oligonucleotide Conjugates Discovery Developing an effective AOC requires more than identifying a receptor. High-quality targeting ligands must combine specificity, internalisation, developability and compatibility with conjugation...
Why VHHs Are Attractive Targeting Ligands for Antibody-Oligonucleotide Conjugates The therapeutic activity of an AOC depends not only on its oligonucleotide payload but also on the targeting ligand that delivers it to the appropriate cells. Selecting the right...
How Are Antibody-Oligonucleotide Conjugates Being Applied? In our previous article, we introduced antibody–oligonucleotide conjugates (AOCs) and explored how they combine targeted delivery with the diverse biological activities of therapeutic oligonucleotides. But how...
Why Antibody–Oligonucleotide Conjugates Are Gaining Momentum Therapeutic oligonucleotides are opening new possibilities for treating diseases that have historically been difficult to address. However, delivering these molecules to the right cells remains one of the...
